ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Adalimumab (Humira) and Biosimilar Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-5D14664
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Adalimumab Humira and Biosimilar Market Research Report 2023
BUY CHAPTERS

Global Adalimumab (Humira) and Biosimilar Market Research Report 2025

Code: QYRE-Auto-5D14664
Report
May 2025
Pages:91
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
AbbVie
Eisai Co Ltd
Cadila Healthcare
Torrent Pharmaceuticals
Amgen Inc
Boehringer Ingelheim
Novartis
Samsung Bioepis
Viatris
Pfizer Inc
Fresenius Kabi
Coherus

Adalimumab (Humira) and Biosimilar Market Size

The global market for Adalimumab (Humira) and Biosimilar was valued at US$ 20310 million in the year 2024 and is projected to reach a revised size of US$ 14120 million by 2031, growing at a CAGR of -5.1% during the forecast period.

Adalimumab (Humira) and Biosimilar Market

Adalimumab (Humira) and Biosimilar Market

Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
The expiration of patents for adalimumab (Humira) has emerged as a significant driver in the biosimilar market. Adalimumab is a widely used biologic medication for autoimmune diseases. The patent expiry allows for the entry of biosimilar versions of Humira, which are highly similar and offer a more cost-effective alternative. This increased competition fosters price reduction and improved accessibility for patients, addressing the growing demand for affordable treatments. Furthermore, regulatory support for biosimilars has further bolstered their adoption, ensuring safety, efficacy, and quality. Overall, the patent expiration and regulatory support are key drivers propelling the adalimumab biosimilar market forward.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Adalimumab (Humira) and Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adalimumab (Humira) and Biosimilar.
The Adalimumab (Humira) and Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Adalimumab (Humira) and Biosimilar market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adalimumab (Humira) and Biosimilar manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Adalimumab (Humira) and Biosimilar Market Report

Report Metric Details
Report Name Adalimumab (Humira) and Biosimilar Market
Accounted market size in year US$ 20310 million
Forecasted market size in 2031 US$ 14120 million
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Syringe
  • Pen
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals, Amgen, Boehringer Ingelheim, Novartis, Samsung Bioepis, Viatris, Pfizer, Fresenius Kabi, Coherus
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Adalimumab (Humira) and Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Adalimumab (Humira) and Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

What is the Adalimumab (Humira) and Biosimilar Market size in 2031?

Ans: The Adalimumab (Humira) and Biosimilar Market size in 2031 will be US$ 14120 million.

Who are the main players in the Adalimumab (Humira) and Biosimilar Market report?

Ans: The main players in the Adalimumab (Humira) and Biosimilar Market are AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals, Amgen, Boehringer Ingelheim, Novartis, Samsung Bioepis, Viatris, Pfizer, Fresenius Kabi, Coherus

What are the Application segmentation covered in the Adalimumab (Humira) and Biosimilar Market report?

Ans: The Applications covered in the Adalimumab (Humira) and Biosimilar Market report are Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s Disease, Other

What are the Type segmentation covered in the Adalimumab (Humira) and Biosimilar Market report?

Ans: The Types covered in the Adalimumab (Humira) and Biosimilar Market report are Syringe, Pen

Recommended Reports

Biosimilars Markets

Autoimmune Diseases

Biologic Therapeutics

1 Adalimumab (Humira) and Biosimilar Market Overview
1.1 Product Definition
1.2 Adalimumab (Humira) and Biosimilar by Type
1.2.1 Global Adalimumab (Humira) and Biosimilar Market Value Comparison by Type (2024 VS 2031)
1.2.2 Syringe
1.2.3 Pen
1.3 Adalimumab (Humira) and Biosimilar by Application
1.3.1 Global Adalimumab (Humira) and Biosimilar Market Value by Application (2024 VS 2031)
1.3.2 Ankylosing Spondylitis
1.3.3 Rheumatoid Arthritis
1.3.4 Crohn’s Disease
1.3.5 Other
1.4 Global Adalimumab (Humira) and Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Adalimumab (Humira) and Biosimilar Revenue 2020-2031
1.4.2 Global Adalimumab (Humira) and Biosimilar Sales 2020-2031
1.4.3 Global Adalimumab (Humira) and Biosimilar Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Adalimumab (Humira) and Biosimilar Market Competition by Manufacturers
2.1 Global Adalimumab (Humira) and Biosimilar Sales Market Share by Manufacturers (2020-2025)
2.2 Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Adalimumab (Humira) and Biosimilar Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Adalimumab (Humira) and Biosimilar, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Adalimumab (Humira) and Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Adalimumab (Humira) and Biosimilar, Product Type & Application
2.7 Global Key Manufacturers of Adalimumab (Humira) and Biosimilar, Date of Enter into This Industry
2.8 Global Adalimumab (Humira) and Biosimilar Market Competitive Situation and Trends
2.8.1 Global Adalimumab (Humira) and Biosimilar Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Adalimumab (Humira) and Biosimilar Players Market Share by Revenue
2.8.3 Global Adalimumab (Humira) and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Adalimumab (Humira) and Biosimilar Market Scenario by Region
3.1 Global Adalimumab (Humira) and Biosimilar Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Adalimumab (Humira) and Biosimilar Sales by Region: 2020-2031
3.2.1 Global Adalimumab (Humira) and Biosimilar Sales by Region: 2020-2025
3.2.2 Global Adalimumab (Humira) and Biosimilar Sales by Region: 2026-2031
3.3 Global Adalimumab (Humira) and Biosimilar Revenue by Region: 2020-2031
3.3.1 Global Adalimumab (Humira) and Biosimilar Revenue by Region: 2020-2025
3.3.2 Global Adalimumab (Humira) and Biosimilar Revenue by Region: 2026-2031
3.4 North America Adalimumab (Humira) and Biosimilar Market Facts & Figures by Country
3.4.1 North America Adalimumab (Humira) and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Adalimumab (Humira) and Biosimilar Sales by Country (2020-2031)
3.4.3 North America Adalimumab (Humira) and Biosimilar Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Adalimumab (Humira) and Biosimilar Market Facts & Figures by Country
3.5.1 Europe Adalimumab (Humira) and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Adalimumab (Humira) and Biosimilar Sales by Country (2020-2031)
3.5.3 Europe Adalimumab (Humira) and Biosimilar Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Adalimumab (Humira) and Biosimilar Market Facts & Figures by Region
3.6.1 Asia Pacific Adalimumab (Humira) and Biosimilar Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Adalimumab (Humira) and Biosimilar Sales by Region (2020-2031)
3.6.3 Asia Pacific Adalimumab (Humira) and Biosimilar Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Adalimumab (Humira) and Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Adalimumab (Humira) and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Adalimumab (Humira) and Biosimilar Sales by Country (2020-2031)
3.7.3 Latin America Adalimumab (Humira) and Biosimilar Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Adalimumab (Humira) and Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Adalimumab (Humira) and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Adalimumab (Humira) and Biosimilar Sales by Country (2020-2031)
3.8.3 Middle East and Africa Adalimumab (Humira) and Biosimilar Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Adalimumab (Humira) and Biosimilar Sales by Type (2020-2031)
4.1.1 Global Adalimumab (Humira) and Biosimilar Sales by Type (2020-2025)
4.1.2 Global Adalimumab (Humira) and Biosimilar Sales by Type (2026-2031)
4.1.3 Global Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2020-2031)
4.2 Global Adalimumab (Humira) and Biosimilar Revenue by Type (2020-2031)
4.2.1 Global Adalimumab (Humira) and Biosimilar Revenue by Type (2020-2025)
4.2.2 Global Adalimumab (Humira) and Biosimilar Revenue by Type (2026-2031)
4.2.3 Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Type (2020-2031)
4.3 Global Adalimumab (Humira) and Biosimilar Price by Type (2020-2031)
5 Segment by Application
5.1 Global Adalimumab (Humira) and Biosimilar Sales by Application (2020-2031)
5.1.1 Global Adalimumab (Humira) and Biosimilar Sales by Application (2020-2025)
5.1.2 Global Adalimumab (Humira) and Biosimilar Sales by Application (2026-2031)
5.1.3 Global Adalimumab (Humira) and Biosimilar Sales Market Share by Application (2020-2031)
5.2 Global Adalimumab (Humira) and Biosimilar Revenue by Application (2020-2031)
5.2.1 Global Adalimumab (Humira) and Biosimilar Revenue by Application (2020-2025)
5.2.2 Global Adalimumab (Humira) and Biosimilar Revenue by Application (2026-2031)
5.2.3 Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Application (2020-2031)
5.3 Global Adalimumab (Humira) and Biosimilar Price by Application (2020-2031)
6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Company Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.1.4 AbbVie Adalimumab (Humira) and Biosimilar Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 Eisai
6.2.1 Eisai Company Information
6.2.2 Eisai Description and Business Overview
6.2.3 Eisai Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Eisai Adalimumab (Humira) and Biosimilar Product Portfolio
6.2.5 Eisai Recent Developments/Updates
6.3 Cadila Healthcare
6.3.1 Cadila Healthcare Company Information
6.3.2 Cadila Healthcare Description and Business Overview
6.3.3 Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Cadila Healthcare Adalimumab (Humira) and Biosimilar Product Portfolio
6.3.5 Cadila Healthcare Recent Developments/Updates
6.4 Torrent Pharmaceuticals
6.4.1 Torrent Pharmaceuticals Company Information
6.4.2 Torrent Pharmaceuticals Description and Business Overview
6.4.3 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product Portfolio
6.4.5 Torrent Pharmaceuticals Recent Developments/Updates
6.5 Amgen
6.5.1 Amgen Company Information
6.5.2 Amgen Description and Business Overview
6.5.3 Amgen Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Amgen Adalimumab (Humira) and Biosimilar Product Portfolio
6.5.5 Amgen Recent Developments/Updates
6.6 Boehringer Ingelheim
6.6.1 Boehringer Ingelheim Company Information
6.6.2 Boehringer Ingelheim Description and Business Overview
6.6.3 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product Portfolio
6.6.5 Boehringer Ingelheim Recent Developments/Updates
6.7 Novartis
6.7.1 Novartis Company Information
6.7.2 Novartis Description and Business Overview
6.7.3 Novartis Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Novartis Adalimumab (Humira) and Biosimilar Product Portfolio
6.7.5 Novartis Recent Developments/Updates
6.8 Samsung Bioepis
6.8.1 Samsung Bioepis Company Information
6.8.2 Samsung Bioepis Description and Business Overview
6.8.3 Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Samsung Bioepis Adalimumab (Humira) and Biosimilar Product Portfolio
6.8.5 Samsung Bioepis Recent Developments/Updates
6.9 Viatris
6.9.1 Viatris Company Information
6.9.2 Viatris Description and Business Overview
6.9.3 Viatris Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Viatris Adalimumab (Humira) and Biosimilar Product Portfolio
6.9.5 Viatris Recent Developments/Updates
6.10 Pfizer
6.10.1 Pfizer Company Information
6.10.2 Pfizer Description and Business Overview
6.10.3 Pfizer Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Pfizer Adalimumab (Humira) and Biosimilar Product Portfolio
6.10.5 Pfizer Recent Developments/Updates
6.11 Fresenius Kabi
6.11.1 Fresenius Kabi Company Information
6.11.2 Fresenius Kabi Description and Business Overview
6.11.3 Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Fresenius Kabi Adalimumab (Humira) and Biosimilar Product Portfolio
6.11.5 Fresenius Kabi Recent Developments/Updates
6.12 Coherus
6.12.1 Coherus Company Information
6.12.2 Coherus Description and Business Overview
6.12.3 Coherus Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Coherus Adalimumab (Humira) and Biosimilar Product Portfolio
6.12.5 Coherus Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Adalimumab (Humira) and Biosimilar Industry Chain Analysis
7.2 Adalimumab (Humira) and Biosimilar Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Adalimumab (Humira) and Biosimilar Production Mode & Process Analysis
7.4 Adalimumab (Humira) and Biosimilar Sales and Marketing
7.4.1 Adalimumab (Humira) and Biosimilar Sales Channels
7.4.2 Adalimumab (Humira) and Biosimilar Distributors
7.5 Adalimumab (Humira) and Biosimilar Customer Analysis
8 Adalimumab (Humira) and Biosimilar Market Dynamics
8.1 Adalimumab (Humira) and Biosimilar Industry Trends
8.2 Adalimumab (Humira) and Biosimilar Market Drivers
8.3 Adalimumab (Humira) and Biosimilar Market Challenges
8.4 Adalimumab (Humira) and Biosimilar Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
AbbVie
Eisai Co Ltd
Cadila Healthcare
Torrent Pharmaceuticals
Amgen Inc
Boehringer Ingelheim
Novartis
Samsung Bioepis
Viatris
Pfizer Inc
Fresenius Kabi
Coherus
List of Tables
 Table 1. Global Adalimumab (Humira) and Biosimilar Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Adalimumab (Humira) and Biosimilar Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Adalimumab (Humira) and Biosimilar Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Adalimumab (Humira) and Biosimilar Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Adalimumab (Humira) and Biosimilar Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Adalimumab (Humira) and Biosimilar Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Adalimumab (Humira) and Biosimilar Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Adalimumab (Humira) and Biosimilar, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Adalimumab (Humira) and Biosimilar, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Adalimumab (Humira) and Biosimilar, Product Type & Application
 Table 12. Global Key Manufacturers of Adalimumab (Humira) and Biosimilar, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Adalimumab (Humira) and Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adalimumab (Humira) and Biosimilar as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Adalimumab (Humira) and Biosimilar Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Adalimumab (Humira) and Biosimilar Sales by Region (2020-2025) & (K Units)
 Table 18. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Region (2020-2025)
 Table 19. Global Adalimumab (Humira) and Biosimilar Sales by Region (2026-2031) & (K Units)
 Table 20. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Region (2026-2031)
 Table 21. Global Adalimumab (Humira) and Biosimilar Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Region (2020-2025)
 Table 23. Global Adalimumab (Humira) and Biosimilar Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Region (2026-2031)
 Table 25. North America Adalimumab (Humira) and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Adalimumab (Humira) and Biosimilar Sales by Country (2020-2025) & (K Units)
 Table 27. North America Adalimumab (Humira) and Biosimilar Sales by Country (2026-2031) & (K Units)
 Table 28. North America Adalimumab (Humira) and Biosimilar Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Adalimumab (Humira) and Biosimilar Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Adalimumab (Humira) and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Adalimumab (Humira) and Biosimilar Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Adalimumab (Humira) and Biosimilar Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Adalimumab (Humira) and Biosimilar Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Adalimumab (Humira) and Biosimilar Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Adalimumab (Humira) and Biosimilar Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Adalimumab (Humira) and Biosimilar Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Adalimumab (Humira) and Biosimilar Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Adalimumab (Humira) and Biosimilar Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Adalimumab (Humira) and Biosimilar Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Adalimumab (Humira) and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Adalimumab (Humira) and Biosimilar Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Adalimumab (Humira) and Biosimilar Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Adalimumab (Humira) and Biosimilar Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Adalimumab (Humira) and Biosimilar Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Adalimumab (Humira) and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Adalimumab (Humira) and Biosimilar Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Adalimumab (Humira) and Biosimilar Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Adalimumab (Humira) and Biosimilar Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Adalimumab (Humira) and Biosimilar Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Adalimumab (Humira) and Biosimilar Sales (K Units) by Type (2020-2025)
 Table 51. Global Adalimumab (Humira) and Biosimilar Sales (K Units) by Type (2026-2031)
 Table 52. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2020-2025)
 Table 53. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2026-2031)
 Table 54. Global Adalimumab (Humira) and Biosimilar Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Adalimumab (Humira) and Biosimilar Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Type (2020-2025)
 Table 57. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Type (2026-2031)
 Table 58. Global Adalimumab (Humira) and Biosimilar Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Adalimumab (Humira) and Biosimilar Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Adalimumab (Humira) and Biosimilar Sales (K Units) by Application (2020-2025)
 Table 61. Global Adalimumab (Humira) and Biosimilar Sales (K Units) by Application (2026-2031)
 Table 62. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Application (2020-2025)
 Table 63. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Application (2026-2031)
 Table 64. Global Adalimumab (Humira) and Biosimilar Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Adalimumab (Humira) and Biosimilar Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Application (2020-2025)
 Table 67. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Application (2026-2031)
 Table 68. Global Adalimumab (Humira) and Biosimilar Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Adalimumab (Humira) and Biosimilar Price (US$/Unit) by Application (2026-2031)
 Table 70. AbbVie Company Information
 Table 71. AbbVie Description and Business Overview
 Table 72. AbbVie Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. AbbVie Adalimumab (Humira) and Biosimilar Product
 Table 74. AbbVie Recent Developments/Updates
 Table 75. Eisai Company Information
 Table 76. Eisai Description and Business Overview
 Table 77. Eisai Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Eisai Adalimumab (Humira) and Biosimilar Product
 Table 79. Eisai Recent Developments/Updates
 Table 80. Cadila Healthcare Company Information
 Table 81. Cadila Healthcare Description and Business Overview
 Table 82. Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Cadila Healthcare Adalimumab (Humira) and Biosimilar Product
 Table 84. Cadila Healthcare Recent Developments/Updates
 Table 85. Torrent Pharmaceuticals Company Information
 Table 86. Torrent Pharmaceuticals Description and Business Overview
 Table 87. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product
 Table 89. Torrent Pharmaceuticals Recent Developments/Updates
 Table 90. Amgen Company Information
 Table 91. Amgen Description and Business Overview
 Table 92. Amgen Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Amgen Adalimumab (Humira) and Biosimilar Product
 Table 94. Amgen Recent Developments/Updates
 Table 95. Boehringer Ingelheim Company Information
 Table 96. Boehringer Ingelheim Description and Business Overview
 Table 97. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product
 Table 99. Boehringer Ingelheim Recent Developments/Updates
 Table 100. Novartis Company Information
 Table 101. Novartis Description and Business Overview
 Table 102. Novartis Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Novartis Adalimumab (Humira) and Biosimilar Product
 Table 104. Novartis Recent Developments/Updates
 Table 105. Samsung Bioepis Company Information
 Table 106. Samsung Bioepis Description and Business Overview
 Table 107. Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Samsung Bioepis Adalimumab (Humira) and Biosimilar Product
 Table 109. Samsung Bioepis Recent Developments/Updates
 Table 110. Viatris Company Information
 Table 111. Viatris Description and Business Overview
 Table 112. Viatris Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Viatris Adalimumab (Humira) and Biosimilar Product
 Table 114. Viatris Recent Developments/Updates
 Table 115. Pfizer Company Information
 Table 116. Pfizer Description and Business Overview
 Table 117. Pfizer Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Pfizer Adalimumab (Humira) and Biosimilar Product
 Table 119. Pfizer Recent Developments/Updates
 Table 120. Fresenius Kabi Company Information
 Table 121. Fresenius Kabi Description and Business Overview
 Table 122. Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Fresenius Kabi Adalimumab (Humira) and Biosimilar Product
 Table 124. Fresenius Kabi Recent Developments/Updates
 Table 125. Coherus Company Information
 Table 126. Coherus Description and Business Overview
 Table 127. Coherus Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Coherus Adalimumab (Humira) and Biosimilar Product
 Table 129. Coherus Recent Developments/Updates
 Table 130. Key Raw Materials Lists
 Table 131. Raw Materials Key Suppliers Lists
 Table 132. Adalimumab (Humira) and Biosimilar Distributors List
 Table 133. Adalimumab (Humira) and Biosimilar Customers List
 Table 134. Adalimumab (Humira) and Biosimilar Market Trends
 Table 135. Adalimumab (Humira) and Biosimilar Market Drivers
 Table 136. Adalimumab (Humira) and Biosimilar Market Challenges
 Table 137. Adalimumab (Humira) and Biosimilar Market Restraints
 Table 138. Research Programs/Design for This Report
 Table 139. Key Data Information from Secondary Sources
 Table 140. Key Data Information from Primary Sources
 Table 141. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Adalimumab (Humira) and Biosimilar
 Figure 2. Global Adalimumab (Humira) and Biosimilar Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Adalimumab (Humira) and Biosimilar Market Share by Type: 2024 & 2031
 Figure 4. Syringe Product Picture
 Figure 5. Pen Product Picture
 Figure 6. Global Adalimumab (Humira) and Biosimilar Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Adalimumab (Humira) and Biosimilar Market Share by Application: 2024 & 2031
 Figure 8. Ankylosing Spondylitis
 Figure 9. Rheumatoid Arthritis
 Figure 10. Crohn’s Disease
 Figure 11. Other
 Figure 12. Global Adalimumab (Humira) and Biosimilar Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Adalimumab (Humira) and Biosimilar Market Size (2020-2031) & (US$ Million)
 Figure 14. Global Adalimumab (Humira) and Biosimilar Sales (2020-2031) & (K Units)
 Figure 15. Global Adalimumab (Humira) and Biosimilar Average Price (US$/Unit) & (2020-2031)
 Figure 16. Adalimumab (Humira) and Biosimilar Report Years Considered
 Figure 17. Adalimumab (Humira) and Biosimilar Sales Share by Manufacturers in 2024
 Figure 18. Global Adalimumab (Humira) and Biosimilar Revenue Share by Manufacturers in 2024
 Figure 19. Global 5 and 10 Largest Adalimumab (Humira) and Biosimilar Players: Market Share by Revenue in Adalimumab (Humira) and Biosimilar in 2024
 Figure 20. Adalimumab (Humira) and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 21. Global Adalimumab (Humira) and Biosimilar Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 22. North America Adalimumab (Humira) and Biosimilar Sales Market Share by Country (2020-2031)
 Figure 23. North America Adalimumab (Humira) and Biosimilar Revenue Market Share by Country (2020-2031)
 Figure 24. United States Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Canada Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Europe Adalimumab (Humira) and Biosimilar Sales Market Share by Country (2020-2031)
 Figure 27. Europe Adalimumab (Humira) and Biosimilar Revenue Market Share by Country (2020-2031)
 Figure 28. Germany Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. France Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. U.K. Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Italy Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Russia Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Adalimumab (Humira) and Biosimilar Sales Market Share by Region (2020-2031)
 Figure 34. Asia Pacific Adalimumab (Humira) and Biosimilar Revenue Market Share by Region (2020-2031)
 Figure 35. China Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Japan Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. South Korea Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. India Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Australia Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. China Taiwan Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Southeast Asia Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Latin America Adalimumab (Humira) and Biosimilar Sales Market Share by Country (2020-2031)
 Figure 43. Latin America Adalimumab (Humira) and Biosimilar Revenue Market Share by Country (2020-2031)
 Figure 44. Mexico Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Brazil Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Argentina Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Middle East and Africa Adalimumab (Humira) and Biosimilar Sales Market Share by Country (2020-2031)
 Figure 48. Middle East and Africa Adalimumab (Humira) and Biosimilar Revenue Market Share by Country (2020-2031)
 Figure 49. Turkey Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Saudi Arabia Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. UAE Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Global Sales Market Share of Adalimumab (Humira) and Biosimilar by Type (2020-2031)
 Figure 53. Global Revenue Market Share of Adalimumab (Humira) and Biosimilar by Type (2020-2031)
 Figure 54. Global Adalimumab (Humira) and Biosimilar Price (US$/Unit) by Type (2020-2031)
 Figure 55. Global Sales Market Share of Adalimumab (Humira) and Biosimilar by Application (2020-2031)
 Figure 56. Global Revenue Market Share of Adalimumab (Humira) and Biosimilar by Application (2020-2031)
 Figure 57. Global Adalimumab (Humira) and Biosimilar Price (US$/Unit) by Application (2020-2031)
 Figure 58. Adalimumab (Humira) and Biosimilar Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Humira Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Adalimumab Monoclonal Antibody Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Adalimumab Market Insights Forecast to 2030
Global Humira Market Insights Forecast to 2030
Global Adalimumab Infliximab And Etanercept Biosimilars Market Research Report 2024
Global Adalimumab Drug Market Research Report 2024
Infliximab and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Remicade Infliximab and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Tumor Necrosis Factor Antibody Market Research Report 2024
Interchangeable Biosimilar Humira Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global TNF Inhibitors for the Treatment of Rheumatoid Arthritis Market Research Report 2024
Global Tumor Necrosis Factor TNF Inhibitor Drugs Market Insights Forecast to 2030
Trastuzumab Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Biosimilars Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Biosimilar of Remicade Market
Global Tocilizumab Biosimilars Market Research Report 2024
Global Tumor Necrosis Factor Alpha Inhibitors Market Research Report 2024
Global Monoclonal antibodies mAbs Biosimilars Market Research Report 2024
Global Tumor Necrosis Factor TNF Antagonists Market Research Report 2024
Remicade infliximab Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions